OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study
Shoucheng Ma, Rui Chen, Ling Duan, et al.
Journal of Gastrointestinal Oncology (2023) Vol. 14, Iss. 2, pp. 1052-1063
Open Access | Times Cited: 17
Shoucheng Ma, Rui Chen, Ling Duan, et al.
Journal of Gastrointestinal Oncology (2023) Vol. 14, Iss. 2, pp. 1052-1063
Open Access | Times Cited: 17
Showing 17 citing articles:
The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review
Deniz Can Güven, Gözde Kavgacı, Enes Erul, et al.
The Oncologist (2024) Vol. 29, Iss. 5, pp. e580-e600
Open Access | Times Cited: 10
Deniz Can Güven, Gözde Kavgacı, Enes Erul, et al.
The Oncologist (2024) Vol. 29, Iss. 5, pp. e580-e600
Open Access | Times Cited: 10
Efficacy and safety of radiotherapy in patients with microsatellite stable or proficient mismatch repair colorectal cancer liver metastasis
Jie Ni, C. W. Wan, Ziqi Sui
World Journal of Gastrointestinal Oncology (2025) Vol. 17, Iss. 3
Closed Access
Jie Ni, C. W. Wan, Ziqi Sui
World Journal of Gastrointestinal Oncology (2025) Vol. 17, Iss. 3
Closed Access
Efficacy and safety of fruquintinib combined with PD-1 inhibitors in the treatment of refractory metastatic colorectal cancer: a systematic review and meta-analysis
Linfeng Liu, Dengzhuo Chen, Liang Wen, et al.
Expert Review of Anticancer Therapy (2025)
Closed Access
Linfeng Liu, Dengzhuo Chen, Liang Wen, et al.
Expert Review of Anticancer Therapy (2025)
Closed Access
Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy
Jing Jiao, You Wu, Shaoxian Wu, et al.
Current Treatment Options in Oncology (2025)
Closed Access
Jing Jiao, You Wu, Shaoxian Wu, et al.
Current Treatment Options in Oncology (2025)
Closed Access
Fruquintinib inhibits the migration and invasion of colorectal cancer cells by modulating epithelial-mesenchymal transition via TGF-β/Smad signaling pathway
Qinqin Song, Hongjiao Wu, Ye Jin, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Qinqin Song, Hongjiao Wu, Ye Jin, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer
Kanchi Patell, Veronica Mears, Michael H. Storandt, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 4, pp. 197-205
Closed Access | Times Cited: 3
Kanchi Patell, Veronica Mears, Michael H. Storandt, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 4, pp. 197-205
Closed Access | Times Cited: 3
Efficacy, safety, and predictors of fruquintinib plus anti-programmed death receptor-1 (PD-1) antibody in refractory microsatellite stable metastatic colorectal cancer in a real-world setting: a retrospective cohort study
Xiaolin Yang, Xianli Yin, Xiaozhou Qu, et al.
Journal of Gastrointestinal Oncology (2023) Vol. 14, Iss. 6, pp. 2425-2435
Open Access | Times Cited: 7
Xiaolin Yang, Xianli Yin, Xiaozhou Qu, et al.
Journal of Gastrointestinal Oncology (2023) Vol. 14, Iss. 6, pp. 2425-2435
Open Access | Times Cited: 7
The intricate dance of tumor evolution: Exploring immune escape, tumor migration, drug resistance, and treatment strategies
Xiaojun Guo, Xiaonan Bian, Yitong Li, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 4, pp. 167098-167098
Closed Access | Times Cited: 2
Xiaojun Guo, Xiaonan Bian, Yitong Li, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 4, pp. 167098-167098
Closed Access | Times Cited: 2
Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy
Kanglian Zheng, Xu Zhu, Liang Xu, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Kanglian Zheng, Xu Zhu, Liang Xu, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study
Hua Bai, Wenhui Wang, Fanfan Zhou, et al.
Cancer Management and Research (2024) Vol. Volume 16, pp. 73-86
Open Access | Times Cited: 1
Hua Bai, Wenhui Wang, Fanfan Zhou, et al.
Cancer Management and Research (2024) Vol. Volume 16, pp. 73-86
Open Access | Times Cited: 1
Clinical research progress of fruquintinib in the treatment of malignant tumors
Shihao Zhao, Wenhui Wang, Jingyi Li, et al.
Investigational New Drugs (2024)
Open Access | Times Cited: 1
Shihao Zhao, Wenhui Wang, Jingyi Li, et al.
Investigational New Drugs (2024)
Open Access | Times Cited: 1
Combination of immunotherapy and fruquintinib in metastatic colorectal cancer: the key to overcome resistance?
Tarek Assi, Mohamad Ali Hachem, Roula Amine-Hneineh, et al.
Immunotherapy (2024), pp. 1-3
Closed Access | Times Cited: 1
Tarek Assi, Mohamad Ali Hachem, Roula Amine-Hneineh, et al.
Immunotherapy (2024), pp. 1-3
Closed Access | Times Cited: 1
Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer
Satoshi Otsu, Shuichi Hironaka
Cancers (2023) Vol. 15, Iss. 18, pp. 4564-4564
Open Access | Times Cited: 3
Satoshi Otsu, Shuichi Hironaka
Cancers (2023) Vol. 15, Iss. 18, pp. 4564-4564
Open Access | Times Cited: 3
Toripalimab and Fruquintinib Therapy for Colorectal Cancer after Failed Multiline Chemotherapies: A Case Report
Ling-Zhijie Kong, Yingjie Zheng, Kaichun Li
Immunotherapy (2023) Vol. 16, Iss. 2, pp. 107-114
Closed Access | Times Cited: 2
Ling-Zhijie Kong, Yingjie Zheng, Kaichun Li
Immunotherapy (2023) Vol. 16, Iss. 2, pp. 107-114
Closed Access | Times Cited: 2
Effectiveness of immune checkpoint inhibitors in combination with tyrosine kinase inhibitors in patients with advanced or metastatic colorectal carcinoma with either mismatch repair proficient or metastatic microsatellite stable disease: A systematic review and meta‑analysis
Li Ji, Jinxian Zhu, Yuxin Zhang, et al.
Oncology Letters (2024) Vol. 27, Iss. 4
Open Access
Li Ji, Jinxian Zhu, Yuxin Zhang, et al.
Oncology Letters (2024) Vol. 27, Iss. 4
Open Access
Brief insight into the in silico properties, structure–activity relationships and biotransformation of fruquintinib, an anticancer drug of a new generation containing a privileged benzofuran scaffold
Dominika Nádaská, Lucia Hudecová, G. Kováč, et al.
Česká a slovenská farmacie (2023) Vol. 72, Iss. 6, pp. 267-275
Closed Access
Dominika Nádaská, Lucia Hudecová, G. Kováč, et al.
Česká a slovenská farmacie (2023) Vol. 72, Iss. 6, pp. 267-275
Closed Access
